17,261 trials
Breast Carcinoma
Primary: Change in Symptom Scores of Vaginal Dryness — -2 units on a scale — p=<0.001
Oral Mucositis
Primary: Cumulative Radiation Dose at Which Severe Oral Mucositis (World Health Organization [WHO] Score ≥ 3) Was First Observed — 66; 56; 48; 60 Cumulative radiation dose (Gy)…
Prostate Cancer
Primary: Overall Time To Progression (TTP) — 6.4 months
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Arm 1: Progression Free Survival (PFS) — 0; 0 Participants
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12…
Pancreatic Neoplasms · Bile Duct Neoplasms
Primary: Overall Response Rate — 1; 1; 3; 1 participants
Seizure Disorder · Hypogonadism · Erectile Dysfunction
Primary: Sexual Function Scores, Calculated Using S-Score and Reynolds' Sexual Questionnaires, Will Increase More Anastrozole and Testosterone Treatment Than With Placebo and…
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) (%) at Week 12 as Compared to Placebo — 0.18; -0.68; -0.91; -0.92 percentage of HbA1c — p=<0.0001
High Grade Glioma
Primary: Event-Free Survival (EFS) as Assessed by the Central Radiology Review Committee (CRRC) — 11.79; 8.21 months — p=0.1292
Psoriatic Arthritis
Primary: American College of Rheumatology (ACR) 20 Response Rate at Week 12: ABT-122 Versus Placebo — 25.0; 64.8; 75.3 percentage of participants — p=<0.001
Male Breast Cancer · Recurrent Breast Cancer · Stage IIIA Breast Cancer
Primary: Safety Evaluated by Collecting Study Related Toxicity as Assessed by CTCAE v3.0 — 15 Participants
Influenza
Primary: Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 H1N1 Strain — 75; 74; 57 Participants
Hepatic Cancer
Primary: Treatment Response — 16; 14; 4 Participants
Rectal Cancer
Primary: Percentage of Participants With Tumor Sterilization Defined by ypT0-N0 — 23.8; 11.4 percentage of participants — p=0.015
Psoriasis
Primary: Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75) — 0; 13; 25; 57…